title: Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains.
abstract: The use of substances that could activate the defective chloride channels of the mutant cystic fibrosis transmembrane conductance regulator (CFTR) has been suggested as possible therapy for cystic fibrosis. Using epithelia formed by cells stably transfected with wildtype or mutant (G551D, G1349D) CFTR, we estimated the apparent dissociation constant, K(D), of a series of CFTR activators by measuring the increase in the apical membrane current. Modification of apparent K(D) of CFTR activators by mutations of the nucleotide-binding domains (NBDs) suggests that the binding site might be in these regions. The human NBD structure was predicted by homology with murine NBD1. An NBD1-NBD2 complex was constructed by overlying monomers to a bacterial ABC transporter NBD dimer in the "head-to-tail" conformation. Binding sites for CFTR activators were predicted by molecular docking. Comparison of theoretical binding free energy estimated in the model to free energy estimated from the apparent dissociation constants, K(D), resulted in a remarkably good correlation coefficient for one of the putative binding sites, located in the interface between NBD1 and NBD2.
authors.affiliation: Istituto di Biofisica, CNR, Via DeMarini 6, 16149 Genoa, Italy. moran@ge.ibf.cnr.it
authors.forename: O
authors.initials: O
authors.lastname: Moran
authors.forename: L J V
authors.initials: LJ
authors.lastname: Galietta
authors.forename: O
authors.initials: O
authors.lastname: Zegarra-Moran
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000819:agonists / Q000235:genetics / Q000502:physiology; D000227:Adenine Nucleotides / Q000378:metabolism; D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites / Q000187:drug effects / Q000235:genetics; D002460:Cell Line; D002463:Cell Membrane Permeability / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D003550:Cystic Fibrosis / Q000188:drug therapy; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000819:agonists* / Q000737:chemistry / Q000235:genetics*; D019281:Dimerization; D004553:Electric Conductivity; D004594:Electrophysiology; D019833:Genistein / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D009154:Mutation / Q000235:genetics; D017434:Protein Structure, Tertiary; D051381:Rats; D016415:Sequence Alignment; D013816:Thermodynamics
chemical_list: D018528:ATP-Binding Cassette Transporters; D000227:Adenine Nucleotides; C505032:CFTR protein, human; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D019833:Genistein
references.citation: Clin Sci (Lond). 2003 Feb;104(2):195-201
references.pmid: 12546642
references.citation: J Clin Endocrinol Metab. 2008 Jun;93(6):2042-9
references.pmid: 18349064
references.citation: J Clin Endocrinol Metab. 2006 Apr;91(4):1305-8
references.pmid: 16434464
references.citation: J Neuroendocrinol. 2011 May;23 (5):456-63
references.pmid: 21332841
references.citation: J Clin Endocrinol Metab. 1999 Feb;84(2):743-50
references.pmid: 10022447
references.citation: Biol Reprod. 2008 Mar;78(3):432-7
references.pmid: 18003947
references.citation: BJU Int. 2016 Aug;118(2):221-9
references.pmid: 26074405
references.citation: J Urol. 1995 Jul;154(1):100-4
references.pmid: 7539852
references.citation: Eur Urol. 2014 Dec;66(6):1101-8
references.pmid: 24440304
references.citation: Br J Pharmacol. 2008 Feb;153(4):693-709
references.pmid: 18157169
references.citation: J Endocrinol. 2013 May 07;217(3):R47-71
references.pmid: 23549841
references.citation: J Gerontol A Biol Sci Med Sci. 2003 Dec;58(12):M1103-10
references.pmid: 14684707
references.citation: Circulation. 2004 Nov 9;110(19):3100-7
references.pmid: 15520315
references.citation: Eur Urol. 2012 Jun;61(6):1119-28
references.pmid: 22336376
references.citation: Eur Urol. 2014 Mar;65(3):565-73
references.pmid: 24210090
references.citation: J Clin Oncol. 2010 Jul 20;28(21):3448-56
references.pmid: 20567006
references.citation: Sci Rep. 2016 May 18;6:26220
references.pmid: 27189011
references.citation: Crit Rev Oncol Hematol. 2013 Apr;86(1):42-51
references.pmid: 23092636
references.citation: Circulation. 2005 Sep 20;112(12):1701-10
references.pmid: 16157773
references.citation: Eur Urol. 2014 Apr;65(4):704-9
references.pmid: 23433805
references.citation: Cancer. 2007 Oct 1;110(7):1493-500
references.pmid: 17657815
references.citation: Pharmacol Res. 2004 Sep;50(3):253-9
references.pmid: 15225667
references.citation: Cancer. 2009 Jun 1;115(11):2388-99
references.pmid: 19399748
references.citation: J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24
references.pmid: 17925537
references.citation: Clin Genitourin Cancer. 2014 Dec;12(6):399-407
references.pmid: 25193364
references.citation: Clin Adv Hematol Oncol. 2006 Sep;4(9):687-96
references.pmid: 17099626
references.citation: J Am Coll Cardiol. 2003 Oct 1;42(7):1306-13
references.pmid: 14522500
references.citation: JAMA. 2011 Dec 7;306(21):2359-66
references.pmid: 22147380
references.citation: Lancet Oncol. 2010 Nov;11(11):1066-73
references.pmid: 20933466
references.citation: Oncology. 2012;82(1):56-8
references.pmid: 22310055
references.citation: Urol Oncol. 2015 Nov;33(11):464-75
references.pmid: 26141678
references.citation: J Clin Oncol. 2009 Jul 20;27(21):3452-8
references.pmid: 19506162
references.citation: J Clin Oncol. 2009 Jan 1;27(1):92-9
references.pmid: 19047297
references.citation: J Am Heart Assoc. 2013 Jul 10;2(4):e000271
references.pmid: 23842280
references.citation: Circulation. 2002 Oct 15;106(16):2132-6
references.pmid: 12379585
references.citation: BJU Int. 2014 Dec;114(6b):E82-E89
references.pmid: 24612110
references.citation: Biochem Biophys Res Commun. 2002 Sep 6;296(5):1051-7
references.pmid: 12207878
references.citation: J Clin Endocrinol Metab. 2002 Feb;87(2):599-603
references.pmid: 11836291
references.citation: Int J Cancer. 2008 Oct 15;123(8):1929-34
references.pmid: 18688863
references.citation: Am J Physiol Heart Circ Physiol. 2006 May;290(5):H2043-50
references.pmid: 16361364
references.citation: Urology. 2008 Feb;71(2):318-22
references.pmid: 18308111
references.citation: Circulation. 2001 Mar 13;103(10):1382-5
references.pmid: 11245640
references.citation: J Clin Oncol. 2006 Sep 20;24(27):4448-56
references.pmid: 16983113
references.citation: Cancer. 2008 May 15;112(10):2188-94
references.pmid: 18348297
references.citation: Cardiovasc Res. 2005 Jan 1;65(1):148-57
references.pmid: 15621042
references.citation: J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23
references.pmid: 23210129
references.citation: J Androl. 2009 Jan-Feb;30(1):23-32
references.pmid: 18772488
references.citation: Endocrinology. 2010 Nov;151(11):5428-37
references.pmid: 20861231
references.citation: J Endocrinol Invest. 2012 Mar;35(3):332-9
references.pmid: 22391014
references.citation: N Engl J Med. 2010 Oct 21;363(17):1621-30
references.pmid: 20961245
references.citation: J Neuroendocrinol. 2009 Mar;21(4):282-92
references.pmid: 19187469